WallStreetZenWallStreetZen

NASDAQ: GERN
Geron Corp Stock

$3.30-0.01 (-0.3%)
Updated Mar 28, 2024
GERN Price
$3.30
Fair Value Price
$3.39
Market Cap
$1.80B
52 Week Low
$1.64
52 Week High
$3.74
P/E
-10.31x
P/B
7.27x
P/S
5,080.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$237.00k
Earnings
-$184.13M
Gross Margin
100%
Operating Margin
-74,183.54%
Profit Margin
-77,690.7%
Debt to Equity
0.59
Operating Cash Flow
-$168M
Beta
0.93
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

GERN Overview

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GERN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GERN ($3.30) is undervalued by 2.77% relative to our estimate of its Fair Value price of $3.39 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
GERN ($3.30) is not significantly undervalued (2.77%) relative to our estimate of its Fair Value price of $3.39 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GERN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GERN due diligence checks available for Premium users.

Be the first to know about important GERN news, forecast changes, insider trades & much more!

GERN News

Valuation

GERN fair value

Fair Value of GERN stock based on Discounted Cash Flow (DCF)
Price
$3.30
Fair Value
$3.39
Undervalued by
2.77%
GERN ($3.30) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GERN ($3.30) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GERN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GERN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-10.31x
Industry
14.26x
Market
44.51x

GERN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.27x
Industry
6.21x
GERN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GERN's financial health

Profit margin

Revenue
$23.0k
Net Income
-$52.0M
Profit Margin
-225,969.6%
GERN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GERN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$394.1M
Liabilities
$146.1M
Debt to equity
0.59
GERN's short-term assets ($341.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GERN's short-term assets ($341.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GERN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GERN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$40.9M
Investing
$47.6M
Financing
$33.3M
GERN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GERN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GERN$1.80B-0.30%-10.31x7.27x
FUSN$1.81B+0.09%-14.70x8.12x
MORF$1.76B+2.36%-9.81x2.53x
CPRX$1.88B-2.03%23.79x4.84x
RCUS$1.72B+3.68%-4.55x3.71x

Geron Stock FAQ

What is Geron's quote symbol?

(NASDAQ: GERN) Geron trades on the NASDAQ under the ticker symbol GERN. Geron stock quotes can also be displayed as NASDAQ: GERN.

If you're new to stock investing, here's how to buy Geron stock.

What is the 52 week high and low for Geron (NASDAQ: GERN)?

(NASDAQ: GERN) Geron's 52-week high was $3.74, and its 52-week low was $1.64. It is currently -11.65% from its 52-week high and 101.22% from its 52-week low.

How much is Geron stock worth today?

(NASDAQ: GERN) Geron currently has 546,059,309 outstanding shares. With Geron stock trading at $3.30 per share, the total value of Geron stock (market capitalization) is $1.80B.

Geron stock was originally listed at a price of $8.25 in Dec 31, 1997. If you had invested in Geron stock at $8.25, your return over the last 26 years would have been -60%, for an annualized return of -3.46% (not including any dividends or dividend reinvestments).

How much is Geron's stock price per share?

(NASDAQ: GERN) Geron stock price per share is $3.30 today (as of Mar 28, 2024).

What is Geron's Market Cap?

(NASDAQ: GERN) Geron's market cap is $1.80B, as of Mar 29, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Geron's market cap is calculated by multiplying GERN's current stock price of $3.30 by GERN's total outstanding shares of 546,059,309.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.